GO:0036085 GDP-fucose import into Golgi lumen

GDP-fucose import into the Golgi lumen (GO:0036085) is a biological process that enables the translocation of the nucleotide sugar GDP-fucose from the cytosol into the lumen of the Golgi apparatus. This transport step is essential because fucosyltransferases, the enzymes that add fucose to glycoproteins and glycolipids, are localized within the Golgi lumen and require GDP-fucose as a substrate. Without efficient import, fucosylation of proteins and lipids is severely impaired, leading to defects in cell adhesion, signaling, and development. The process is conserved across eukaryotes, from plants to humans, and is mediated by specific membrane transporters. Researchers study GO:0036085 to understand fundamental glycosylation mechanisms and to model human diseases such as congenital disorders of glycosylation (CDG). The identification of the GDP-fucose transporter SLC35C1 (also known as FUCT1) as the gene mutated in CDG-IIc provided a direct link between this transport process and human pathology. In plants, the Golgi-localized GDP-L-fucose transporter GFT1 is required for normal development, underscoring the broad biological importance of this import step. In Drosophila, redundant pathways for GDP-fucose import into the endoplasmic reticulum lumen support Notch O-fucosylation, revealing additional layers of regulation. This article integrates authoritative QuickGO data with verified PubMed literature to provide a comprehensive overview of the genes, mechanisms, and research methods associated with GDP-fucose import into the Golgi lumen. It is designed for researchers seeking to generate CRISPR models, interpret glycosylation phenotypes, or develop therapeutic strategies targeting fucosylation pathways.

GO:0036085, GDP-fucose import into Golgi lumen, is defined as the directed movement of GDP-fucose into the Golgi lumen. GDP-fucose is a nucleotide sugar composed of fucose in glycosidic linkage with guanosine diphosphate. This process is a type of transmembrane transport that delivers the substrate required for fucosylation reactions within the Golgi apparatus.

GDP-fucose import into the Golgi lumen is a rate-limiting step for fucosylation, a post-translational modification that regulates protein stability, cell adhesion, and receptor signaling. Defects in this process cause CDG-IIc, a rare but severe immunodeficiency characterized by leukocyte adhesion deficiency and developmental delay. The evolutionary conservation of this transport mechanism, from plants to insects to humans, highlights its fundamental role in eukaryotic biology. Studying GO:0036085 provides insights into glycosylation-related diseases and offers targets for glycoengineering and therapeutic intervention.

The following genes and proteins are directly involved in GDP-fucose import into the Golgi lumen or in related fucosylation pathways.

The import of GDP-fucose into the Golgi lumen is regulated at multiple levels. Expression of the transporter SLC35C1 can be modulated by cellular demands for fucosylation, and its activity may be influenced by the availability of cytosolic GDP-fucose. In Drosophila, two redundant pathways for GDP-fucose import into the ER lumen ensure sufficient substrate for Notch O-fucosylation, suggesting that redundancy provides robustness. Additionally, feedback mechanisms may adjust the synthesis of GDP-fucose in the cytosol to match Golgi import capacity.

Mutations in the SLC35C1 gene, which encodes the Golgi GDP-fucose transporter, cause CDG-IIc, also known as leukocyte adhesion deficiency type II. This disorder is characterized by severe immunodeficiency, recurrent infections, and developmental delay due to defective fucosylation of selectins and other glycoproteins. The discovery of SLC35C1 as the causative gene established a direct link between GDP-fucose import into the Golgi lumen and human disease.

Impaired GDP-fucose import leads to defective synthesis of sialyl Lewis X, a fucosylated glycan required for leukocyte rolling and adhesion. This results in leukocyte adhesion deficiency, a condition marked by high neutrophil counts and recurrent bacterial infections.

Altered fucosylation is a hallmark of cancer, affecting cell adhesion, migration, and immune evasion. Although direct mutations in GDP-fucose transporters are rare in cancer, dysregulation of fucosylation pathways, including GDP-fucose import, can contribute to tumor progression and metastasis.

Mass spectrometry-based glycomics can quantify fucosylated glycans in cells with altered GDP-fucose import. This method reveals the downstream impact of transporter mutations on protein and lipid fucosylation.

Fluorescently labeled lectins, such as Ulex europaeus agglutinin I (UEA-I), bind fucose and can be used to assess cell surface fucosylation by flow cytometry. This is a rapid way to screen for defects in GDP-fucose import.

In vitro transport assays using radioactive GDP-fucose and Golgi membrane vesicles can directly measure import activity. This method is useful for characterizing transporter mutants.

Genome-wide CRISPR knockout screens can identify genes required for GDP-fucose import and fucosylation. Cells are selected with lectins or antibodies against fucosylated epitopes to enrich for transporters and pathway components.

Researchers studying GDP-fucose import into Golgi lumen-related genes often need to determine whether a candidate gene is causally involved in fucosylation defects, developmental phenotypes, or disease. EDITGENE provides comprehensive CRISPR services to generate precisely engineered cell models for such investigations.

GDP-fucose import into the Golgi lumen (GO:0036085) is a fundamental biological process that supplies the substrate for fucosylation, a modification critical for cell adhesion, signaling, and development. Defects in this process cause CDG-IIc and contribute to other pathologies, making it a valuable target for research and therapeutic intervention. The conservation of this transport mechanism across eukaryotes underscores its importance and provides diverse model systems for study. EDITGENE offers a full suite of CRISPR services, including knockout, point mutation, knock-in, overexpression, and library screening, to help researchers dissect the genes and pathways involved in GDP-fucose import. By leveraging these tools, scientists can accelerate discoveries in glycosylation biology and develop novel treatments for related diseases.